My bush man science understanding is that the 2RT is effective for a sub-set of patients with intermediate AMD (i.e. those who did not have coexistent reticular pseudodrusen (RPD)). It would be good to understand how much of the US$10bn market is now available to them and also the size of the VEGF market for patients not having RPD. The investor call tomorrow should be very informative.
Ann: ELX LEAD Clinical trial results, page-9
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.52M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.0¢ | 19.0¢ | $22.41K | 115.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 109923 | 3 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |